The eyes don't see what the mind doesn't know: discovering monoclonal gammopathy of thrombotic or thrombocytopenic significance
DOI:
https://doi.org/10.18203/2320-6012.ijrms20232823Keywords:
Monoclonal gammopathy, Thombosis, MGTSAbstract
A new scientific advancement in the field of medicine has been made thanks to the collaboration between the university of Michigan health and mayo clinic. A previously undiscovered illness has been named Monoclonal Gammopathy of Thrombotic/Thrombocytopenic Significance (MGTS) as a result of thorough investigation and the convergence of facts. The ramifications of this discovery for medical professionals are considerable, and they may lead to a radical change in how we approach patient care, diagnosis, and treatment.
Metrics
References
Kanack AJ, Schaefer JK, Sridharan M, Splinter NP, Kohlhagen MC, Singh B et al. Monoclonal gammopathy of thrombotic/thrombocytopenic significance. Blood. 2023;141(14):1772-6.
Lach B, Rippstein P, Atack D, Afar DE, Gregor A. Immunoelectron microscopic localization of monoclonal IgM antibodies in gammopathy associated with peripheral demyelinative neuropathy. Acta neuropathologica. 1993;85(3):298-307.
Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clinic Proceedings. 2017;92(5):838-50.
Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology (Amsterdam, Netherlands). 2012;17(1):S177-80.